Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens

Morrisette, Taylor; Alosaimy, Sara; Lagnf, Abdalhamid M; Frens, Jeremy J; Webb, Andrew; Veve, Michael P; Stevens, Ryan W; Bouchard, Jeannette; Gore, Tristan; Ansari, Iman

doi:10.1007/s40121-022-00645-5

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, eravacycline (and tigecycline) are generally avoided for bloodstream infections [ 7 ]. Omadacycline shows in vitro activity against A. baumanni , but its activity is reduced against drug-resistant strains and clinical data are limited to case series [ 61 , 62 ]. While omadacycline has some favorable characteristics (oral formulation and well-tolerated), its poorer in vitro activity compared with eravacycline against drug-resistant strains and limited clinical data are why it is not recommended for treatment of CRAB infections [ 7 ].…”

Section: Results For Sulbactam–durlobactam Compared With Other Antibi...mentioning

confidence: 99%

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

McLeod,

O'Donnell,

Narayanan

et al. 2024

Future Microbiology

View full text Add to dashboard Cite

Sulbactam–durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against Acinetobacter but is prone to hydrolysis by β-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane β-lactamase inhibitor with activity against Ambler classes A, C and D serine β-lactamases that restores sulbactam activity both in vitro and in vivo against multidrug-resistant ABC. Sulbactam–durlobactam is a promising alternative therapy for the treatment of serious Acinetobacter infections, which can have high rates of mortality.

show abstract

Section: Results For Sulbactam–durlobactam Compared With Other Antibi...mentioning

confidence: 99%

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

McLeod,

O'Donnell,

Narayanan

et al. 2024

Future Microbiology

View full text Add to dashboard Cite

show abstract

“…In recent years, multidrug-resistant (MDR)/extensively drug-resistant (XDR) bacteria have also been isolated from cSSTIs (such as MDR/XDR Enterobacteriaceae ) [ 35 ]. A multicenter, observational study involving nine patients has found that oral OMC (450 mg loading dose plus 300 mg maintenance dose) is effective against MDR E. coli and K. pneumoniae -induced bone/joint or intra-abdominal infection [ 37 ]. Since LZD is not active against Gram-negative pathogens [ 38 , 39 ], patients with sole Gram-negative pathogenic bacterial infections were excluded from RCTs.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials

Liang,

Yin,

Chen

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Objective In the present study, we aimed to compare the clinical efficacy and safety of omadacycline (OMC) with its comparators for the treatment of complicated skin and soft tissue infections (cSSTIs) in adult patients. Methods Randomized controlled trials (RCTs) evaluating OMC for cSSTIs were searched in databases of PubMed, Embase, Cochrane, Web of Science, and Clinical Trial, up to July 2022. The primary outcomes were clinical efficacy and microbiological response, with secondary outcome was safety. Results Four RCTs consisting of 1,757 patients were included, with linezolid (LZD) as a comparator drug. For clinical efficacy, OMC was not inferior to LZD in the modified intent-to-treat (MITT) (OR: 1.24, 95% Cl: [0.93, 1.66], P = 0.15) and clinically evaluable (CE) populations (OR: 1.92, 95% Cl: [0.94, 3.92], P = 0.07). For microbiological response, OMC was numerically higher than LZD in the microbiologically evaluable (ME) (OR: 1.74, 95% Cl: [0.81, 3.74], P = 0.16) and microbiological MITT (micro-MITT) populations (OR: 1.27, 95% Cl: [0.92, 1.76], P = 0.14). No significant difference was found in subpopulations of monomicrobial or polymicrobial mixed infection populations. The mortality and adverse event rates were similar between OMC and LZD. Conclusions OMC was as good as LZD in terms of clinical efficacy and microbiological response, and has similar safety issues in treating cSSTIs. OMC might be a promising option for treating cSSTIs in adult patients.

show abstract

“…Of great interest is its oral administration. A multicentre study reported nine cases treated with oral OMA, mainly osteoarticular or intra-abdominal infections caused by MDR or XDR AB CRAB, with promising results [141 ▪ ].…”

Section: What Is the Role Of Old And New Tetracyclines?mentioning

confidence: 99%

How to treat severe Acinetobacter baumannii infections

Bouza,

Muñoz,

Burillo

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review To update the management of severe Acinetobacter baumannii infections (ABI), particularly those caused by multi-resistant isolates. Recent findings The in vitro activity of the various antimicrobial agents potentially helpful in treating ABI is highly variable and has progressively decreased for many of them, limiting current therapeutic options. The combination of more than one drug is still advisable in most circumstances. Ideally, two active first-line drugs should be used. Alternatively, a first-line and a second-line drug and, if this is not possible, two or more second-line drugs in combination. The emergence of new agents such as Cefiderocol, the combination of Sulbactam and Durlobactam, and the new Tetracyclines offer therapeutic options that need to be supported by clinical evidence. Summary The apparent limitations in treating infections caused by this bacterium, the rapid development of resistance, and the serious underlying situation in most cases invite the search for alternatives to antibiotic treatment, the most promising of which seems to be bacteriophage therapy.

show abstract

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens

Cited by 5 publications

References 22 publications

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials

How to treat severe Acinetobacter baumannii infections

Contact Info

Product

Resources

About